Biochemistry Quiz: Cholesterol Biosynthesis And The Mevalonate Pathway

What this quiz covers

This quiz focuses on Cholesterol Biosynthesis And The Mevalonate Pathway, giving you a quick way to practice the rules, question types, and explanations that matter most for Biochemistry.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Citrate acts as a direct allosteric activator of HMG-CoA reductase, increasing the rate of the committed step.
2. Citrate inhibits phosphofructokinase-1, redirecting glycolytic intermediates toward NADPH production.
3. Citrate is transported to the cytosol and cleaved by ATP-citrate lyase to generate the cytosolic acetyl-CoA required for the pathway. (correct answer)
4. High citrate signals the dephosphorylation of HMG-CoA reductase via insulin-stimulated protein phosphatases.

Explanation: Acetyl-CoA, the building block for cholesterol, is produced in the mitochondria. However, cholesterol synthesis occurs in the cytosol. Acetyl-CoA cannot cross the inner mitochondrial membrane directly. Instead, it condenses with oxaloacetate to form citrate. When energy levels are high, citrate accumulates and is transported to the cytosol via the citrate transporter. In the cytosol, the enzyme ATP-citrate lyase cleaves citrate back into acetyl-CoA and oxaloacetate, providing the necessary substrate for cholesterol and fatty acid synthesis.

Question 2

1. Alternative pathways for cholesterol synthesis bypass the mevalonate step entirely, utilizing direct cyclization of squalene precursors from fatty acid metabolism
2. Residual HMG-CoA reductase activity produces sufficient mevalonate below detection limits, while compensatory upregulation of downstream enzymes amplifies the remaining flux (correct answer)
3. Cellular cholesterol pools are being maintained through enhanced recycling of cholesteryl esters stored in lipid droplets rather than de novo synthesis
4. The $^{14}C$-acetate incorporation is measuring ketone body synthesis rather than cholesterol synthesis due to overlapping metabolic intermediates

Explanation: Even very low levels of HMG-CoA reductase activity can produce mevalonate below detection limits. The cell responds to cholesterol depletion by upregulating SREBP-2, which increases expression of all cholesterol biosynthetic enzymes downstream of HMG-CoA reductase. This coordinate upregulation can amplify the flux through the remaining functional enzyme, maintaining significant cholesterol synthesis even when mevalonate is undetectable. Choice A is incorrect because there are no known alternative pathways that bypass mevalonate. Choice C doesn't explain continued $^{14}C$-acetate incorporation. Choice D is wrong because the assay conditions would distinguish between cholesterol and ketone body synthesis.

Question 3

1. Accumulated 7-dehydrocholesterol competitively inhibits lanosterol 14α-demethylase, creating a bottleneck that causes upstream intermediate accumulation throughout the post-squalene pathway
2. The genetic defect causes compensatory upregulation of squalene synthase and cyclase activities, overwhelming the capacity of downstream enzymes to process lanosterol efficiently
3. Loss of cholesterol end-product inhibition triggers SREBP-2 activation, increasing flux into the pathway while the final step blockade causes backup of intermediates including lanosterol (correct answer)
4. 7-dehydrocholesterol reductase normally provides allosteric activation to multiple upstream enzymes, and its absence reduces their activity causing lanosterol accumulation

Explanation: In Smith-Lemli-Opitz syndrome, the block in cholesterol synthesis reduces cellular cholesterol levels, which relieves end-product inhibition and activates SREBP-2. This increases transcription of all cholesterol biosynthetic enzymes, driving more flux into the pathway. However, since the final step is blocked, intermediates including both 7-dehydrocholesterol (immediately upstream of the block) and lanosterol (further upstream) accumulate because the pathway is essentially 'backed up' like a traffic jam. Choice A is incorrect because 7-dehydrocholesterol doesn't inhibit lanosterol demethylase. Choice B is wrong because the defect is downstream, not in squalene enzymes. Choice D is incorrect because 7-dehydrocholesterol reductase doesn't provide allosteric regulation to upstream enzymes.

Question 4

1. It prevents excessive consumption of ATP during periods when isoprenoid synthesis is already adequate, conserving energy for other cellular processes during rapid growth
2. It ensures balanced production of different isoprenoid products by limiting early pathway flux when downstream branching toward protein prenylation is highly active
3. It coordinates cholesterol synthesis with membrane biogenesis by sensing the availability of isoprenoid units needed for sterol incorporation into growing membranes
4. It provides negative feedback control to prevent overproduction of mevalonate-derived metabolites when sufficient isoprenoid precursors are already available for cellular needs (correct answer)

Explanation: When you encounter enzyme regulation questions involving feedback inhibition, focus on identifying the relationship between the inhibitor and its position in the metabolic pathway. This question tests your understanding of negative feedback control in the mevalonate pathway. Geranyl pyrophosphate (GPP) is a downstream product of the mevalonate pathway, and it's inhibiting phosphomevalonate kinase, an upstream enzyme. This is classic negative feedback inhibition. When GPP concentrations are high (40 μM, well above the $K_i$ of 15 μM), it signals that sufficient isoprenoid products have been made, so the pathway should slow down. The 70% reduction in enzyme activity (to 30% maximum) demonstrates potent inhibition that prevents wasteful overproduction of mevalonate-derived compounds. Answer D correctly identifies this as negative feedback control preventing overproduction when adequate isoprenoid precursors exist. This is the fundamental principle of metabolic regulation. Answer A focuses on ATP conservation, but feedback inhibition primarily prevents product overaccumulation, not energy conservation. Answer B suggests this regulates branching between different isoprenoid products, but phosphomevalonate kinase acts early in the pathway before major branching occurs. Answer C specifically mentions cholesterol synthesis coordination, but GPP inhibition affects the entire mevalonate pathway, not just cholesterol production. Remember: negative feedback inhibition occurs when a downstream product inhibits an upstream enzyme. Look for the inhibitor's position relative to the enzyme in the pathway – if the inhibitor comes after the enzyme in the metabolic sequence, it's likely negative feedback control.

Question 5

1. Accumulated farnesyl-PP is redirected toward protein prenylation reactions and synthesis of coenzyme Q10, dolichol, and other essential isoprenoids that share common precursors (correct answer)
2. Blocked squalene formation triggers compensatory activation of alternative sterol synthesis pathways that produce steroid hormone precursors and bile acid intermediates
3. Squalene synthase inhibition activates futile cycling between mevalonate and isopentenyl pyrophosphate, leading to energy waste and accumulation of pathway intermediates
4. The inhibitor causes allosteric activation of upstream enzymes in the mevalonate pathway, resulting in overproduction of geranyl-PP and its subsequent conversion to monoterpenes

Explanation: When squalene synthase is inhibited, farnesyl pyrophosphate cannot be converted to squalene for cholesterol synthesis. The accumulated FPP is then redirected into alternative biosynthetic pathways that produce other essential isoprenoid compounds. These include protein prenylation (farnesylation and geranylgeranylation), coenzyme Q10 synthesis, dolichol synthesis for protein glycosylation, and other non-sterol isoprenoids. This metabolic rerouting explains the accumulation of these compounds. Choice B is incorrect because steroid hormones and bile acids are derived from cholesterol, not from alternative pathways. Choice C is wrong because there's no futile cycling in this pathway. Choice D is incorrect because the inhibitor is specific for squalene synthase and wouldn't cause allosteric effects on upstream enzymes.

Question 6

1. CoQ10 synthesis utilizes an alternative mevalonate-independent pathway involving direct condensation of aromatic amino acids with isoprenoid units from carotenoid metabolism
2. The remaining FPP synthesis (35% inhibition) is sufficient for CoQ10 production because its synthesis requires only one FPP molecule, while cholesterol requires multiple condensation steps
3. CoQ10 synthesis can utilize geranyl-PP directly without requiring FPP, while cholesterol synthesis has an absolute requirement for FPP-derived squalene formation (correct answer)
4. CoQ10 biosynthesis involves salvage pathways that recycle existing isoprenoid side chains, reducing dependence on de novo FPP synthesis compared to cholesterol

Explanation: CoQ10 (ubiquinone) synthesis requires a 10-unit isoprenoid side chain that can be synthesized directly from geranyl pyrophosphate (GPP) and isopentenyl pyrophosphate without requiring farnesyl pyrophosphate. In contrast, cholesterol synthesis has an absolute requirement for FPP because two FPP molecules must condense to form squalene, which is then cyclized to cholesterol. When FPP synthesis is blocked, cholesterol production is severely impaired, but CoQ10 can still be made using the alternative GPP pathway. Choice A is incorrect because there are no known mevalonate-independent pathways for CoQ10. Choice B misunderstands the stoichiometry - cholesterol actually requires 2 FPP molecules. Choice D is incorrect because salvage pathways don't significantly contribute to isoprenoid biosynthesis in this timeframe.

Question 7

1. Fasting conditions reduce NADPH availability from the pentose phosphate pathway, limiting the reductase reaction even when the enzyme is dephosphorylated and fully active (correct answer)
2. Elevated glucagon during fasting maintains cAMP levels that activate PKA, which phosphorylates additional inhibitory sites on HMG-CoA reductase not affected by alkaline phosphatase
3. Increased fatty acid oxidation during fasting produces acetyl-CoA that competes with HMG-CoA for the reductase active site, maintaining competitive inhibition
4. Fasting activates Insig proteins through sterol-independent mechanisms, promoting continued proteasomal degradation of a fraction of the reductase protein pool

Explanation: During fasting, glucose metabolism decreases, reducing flux through the pentose phosphate pathway, which is the primary source of NADPH. HMG-CoA reductase requires NADPH as a cofactor for the reduction of HMG-CoA to mevalonate. Even when the enzyme is dephosphorylated and theoretically active, insufficient NADPH availability limits the reaction rate. This explains why activity only partially recovers after phosphatase treatment. Choice B is incorrect because PKA doesn't directly phosphorylate HMG-CoA reductase. Choice C is wrong because acetyl-CoA doesn't compete with HMG-CoA at the active site. Choice D is incorrect because Insig activation during fasting is primarily sterol-dependent and wouldn't explain the partial recovery after dephosphorylation.

Question 8

1. Temperature stress combined with SCAP dysfunction causes ER calcium release, activating calcium-dependent proteases that specifically degrade HMG-CoA reductase protein
2. Inactive SCAP cannot transport cholesterol to the ER membrane, causing sterol accumulation that directly inhibits HMG-CoA reductase enzyme activity through allosteric mechanisms
3. SCAP inactivation triggers a stress response that activates AMPK, leading to inhibitory phosphorylation of HMG-CoA reductase and subsequent enzyme degradation
4. Loss of SCAP function prevents SREBP-2 processing, eliminating transcriptional activation of HMG-CoA reductase genes and causing enzyme levels to decrease as existing proteins undergo normal turnover (correct answer)

Explanation: When you encounter questions about cholesterol homeostasis and SREBP regulation, focus on the pathway from sterol sensing to gene transcription. The SREBP system controls cholesterol synthesis primarily through transcriptional regulation, not direct enzyme modification. SCAP (SREBP cleavage-activating protein) is essential for SREBP-2 processing and activation. Under low cholesterol conditions, SCAP escorts SREBP-2 from the ER to the Golgi, where proteases cleave SREBP-2 to release its active transcription factor domain. This active SREBP-2 then enters the nucleus and upregulates genes encoding cholesterol synthesis enzymes, including HMG-CoA reductase. When SCAP becomes inactive at 42°C, SREBP-2 cannot be processed and activated. Without functional SREBP-2 transcription factors, HMG-CoA reductase gene transcription stops. Since cyclohexamide blocks new protein synthesis (confirming the transcriptional mechanism), existing HMG-CoA reductase enzymes gradually disappear through normal protein turnover, explaining the 3-hour timeframe for activity to drop to 20%. Option A incorrectly invokes calcium-dependent proteases, which aren't part of the SREBP pathway. Option B mischaracterizes SCAP's function—it doesn't transport cholesterol but rather escorts SREBP-2 for processing. Option C suggests AMPK activation, but temperature-induced SCAP inactivation doesn't trigger AMPK, and the cyclohexamide experiment rules out this mechanism. Remember: SREBP regulation primarily controls cholesterol homeostasis through transcriptional control, not post-translational enzyme modifications. When you see SCAP/SREBP questions, think "gene expression" first.

Question 9

1. 25-HC binds directly to HMG-CoA reductase and targets it for proteasomal degradation while simultaneously activating SCAP to retain SREBP-2 in the ER
2. 25-HC activates Insig proteins, which promote HMG-CoA reductase degradation and block SREBP-2 transport to the Golgi regardless of sterol sensor domain occupancy (correct answer)
3. 25-HC depletes cellular ATP pools required for HMG-CoA reductase stability, while energy stress prevents SREBP-2 processing through AMPK activation
4. 25-HC functions as an LXR ligand, inducing transcription of cholesterol efflux pumps that rapidly deplete ER cholesterol stores below detection limits

Explanation: 25-hydroxycholesterol is a potent activator of Insig proteins (Insig-1 and Insig-2). Activated Insig proteins have two key functions: they promote ubiquitination and proteasomal degradation of HMG-CoA reductase (explaining the rapid protein loss without mRNA changes), and they bind to SCAP preventing SREBP-2 transport from ER to Golgi for processing. This dual mechanism allows 25-HC to suppress cholesterol synthesis even when ER cholesterol levels appear normal. Choice A is incorrect because 25-HC doesn't bind directly to HMG-CoA reductase and doesn't activate SCAP. Choice C is wrong because 25-HC doesn't significantly affect ATP levels. Choice D is incorrect because LXR activation wouldn't explain the direct effects on HMG-CoA reductase protein levels.